Additionally, vMIP‐II‐TAT‐I showed higher selectivity for AML cells, achieving a greater SI than AT‐101, a known MCL‐1/BCL‐xL inhibitor. This evidence concerns the gene BCL2L1 and acute myeloid leukemia.